ACER THERAPEUTICS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
ACER THERAPEUTICS INC. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $15.46 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-20.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2023-11-20
- ACER THERAPEUTICS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-09-30 was $1.72M.
- ACER THERAPEUTICS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-06-30 was $23.89M.
- ACER THERAPEUTICS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-03-31 was -$10.16M, a 1155.36% decline year-over-year.
- ACER THERAPEUTICS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2022-12-31 was $3.53M.
- ACER THERAPEUTICS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$558.21K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | $25.62M derived: sum of 2 quarters · filed 2023-11-20 | $15.46M 10-Q · filed 2023-11-20 | $18.99M derived: sum of 4 quarters · filed 2023-11-20 |
| 2023-06-30 | $23.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $13.74M 10-Q · filed 2023-08-14 | $17.27M derived: sum of 3 quarters · filed 2023-08-14 | $16.95M derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | -$10.16M 10-Q · filed 2023-05-15 | -$6.62M derived: sum of 2 quarters · filed 2023-05-15 | -$6.95M derived: sum of 3 quarters · filed 2023-05-15 | -$11.68M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $3.21M derived: sum of 2 quarters · filed 2023-03-27 | -$1.52M derived: sum of 3 quarters · filed 2023-03-27 | -$558.21K 10-K · filed 2023-03-27 |
| 2022-09-30 | -$324.55K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-14 | -$5.05M derived: sum of 2 quarters · filed 2022-11-14 | -$4.09M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$4.73M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-11-14 | -$3.77M 10-Q/A · filed 2022-11-14 | ||
| 2022-03-31 | $962.40K 10-Q · filed 2023-05-15 |